Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety.
Sugitani I, Ueda S, Sakurai T, Shigekawa T, Hirokawa E, Shimada H, Takeuchi H, Matsuura K, Misumi M, Fujiuchi N, Takahashi T, Hasebe T, Osaki A, Saeki T. Sugitani I, et al. Among authors: ueda s. Int J Clin Oncol. 2017 Oct;22(5):880-886. doi: 10.1007/s10147-017-1136-8. Epub 2017 May 25. Int J Clin Oncol. 2017. PMID: 28547525 Free PMC article. Clinical Trial.
18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response.
Ueda S, Saeki T, Shigekawa T, Omata J, Moriya T, Yamamoto J, Osaki A, Fujiuchi N, Misumi M, Takeuchi H, Sakurai T, Tsuda H, Tamura K, Ishida J, Abe Y, Imabayashi E, Kuji I, Matsuda H. Ueda S, et al. Int J Clin Oncol. 2012 Jun;17(3):276-82. doi: 10.1007/s10147-011-0287-2. Epub 2011 Aug 10. Int J Clin Oncol. 2012. PMID: 21830087
Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.
Shigekawa T, Osaki A, Sekine H, Sato N, Kanbayashi C, Sano H, Takeuchi H, Ueda S, Nakamiya N, Sugitani I, Sugiyama M, Shimada H, Hirokawa E, Takahashi T, Saeki T. Shigekawa T, et al. Among authors: ueda s. BMC Cancer. 2015 Apr 10;15:253. doi: 10.1186/s12885-015-1289-7. BMC Cancer. 2015. PMID: 25884795 Free PMC article.
Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H, Ueda S, Saeki T, Shigekawa T, Takeuchi H, Hirokawa E, Sugitani I, Sugiyama M, Takahashi T, Matsuura K, Yamane T, Kuji I, Hasebe T, Osaki A. Shimada H, et al. Among authors: ueda s. Jpn J Clin Oncol. 2015 Jul;45(7):642-9. doi: 10.1093/jjco/hyv055. Epub 2015 May 19. Jpn J Clin Oncol. 2015. PMID: 25989989 Clinical Trial.
Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, Ishida J, Tamura K, Abe Y, Moriya T, Yamamoto J. Ueda S, et al. Breast Cancer. 2011 Oct;18(4):299-308. doi: 10.1007/s12282-010-0212-y. Epub 2010 Jul 9. Breast Cancer. 2011. PMID: 20617404 Clinical Trial.
3,148 results